





## Memorandum – POC #6

To: UNC Eastowne Medical Center Clinic Physicians

From:  Nichole Korpi-Steiner, Ph.D.  
Director, UNCCMC Point of Care Testing

 Jason Merker, M.D., Ph.D.  
Medical Director, Eastowne Medical Center Laboratories

 Herbert C. Whinna, M.D., Ph.D.  
Medical Director, UNCCMC McLendon Clinical Laboratories

Date: February 28, 2025

Subject: **Point-of-Care HbA1c testing using reagent lot # 0841121**

---

**Effective February 28<sup>th</sup>, 2025, point-of-care HbA1c testing using the Siemens DCA Vantage Reagent lot # 0841121 should implement an intercept offset (0.3%).**

Evaluation of DCA reagent lot # 0841121 demonstrated a negative bias (falsely low) in measured values compared to lab testing; accordingly, an intercept offset of 0.3% is needed to better align POC HbA1c results with lab testing. **This intercept offset is specific to this reagent lot # 0841121.** Additional lot sequestering and evaluation for potential modification of intercept offset should be performed.

### Recommendations for CLIA Medical Director(s):

- If DCA Vantage reagent lot # 0841121 was purchased and received, program the DCA Vantage analyzer(s) with intercept offset of 0.3% prior to patient testing.
- Report any patient safety incident(s) via online SAFE reporting system.

If indicated, submit official complaint regarding DCA Vantage performance to Siemens Healthineers by calling Technical Support line at 1-877-229-3711, prompt 14, then prompt 1.

If you have any questions related to these changes, please contact Dr. Korpi-Steiner at 984-974-1498 or [Nichole.korpi-steiner@unchealth.unc.edu](mailto:Nichole.korpi-steiner@unchealth.unc.edu)